Drugs / JNJ-78934804
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT05242484 | Sep 2022 → May 2025 overdue | ulcerative colitis | Janssen Research & Development, LLC | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05242471 | Jul 2022 → May 2025 overdue | Crohn disease | Janssen Research & Development, LLC | Active not recruiting | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT07577856 | May 2026 → Aug 2028 expected | ulcerative colitis | Janssen Research & Development, LLC | Recruiting | No outcome recorded |
| Phase 3 | NCT07577843 | May 2026 → Jun 2028 expected | Crohn disease | Janssen Research & Development, LLC | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2026-05-05 | Janssen Research & Development, LLC | Results Johnson & Johnson investigational co-antibody therapy JNJ-4804 shows potential to raise the bar for clinical efficacy in treating refractory inflammatory bowel disease jnj.com ↗
In both studies at Week 48, JNJ-4804 showed meaningful improvements across multiple clinical and endoscopic measures for a subpopulation of patients who are considered highly refractory and have had inadequate response to two or more systemic therapy classes. |
| 2026-05-05 | Janssen Research & Development, LLC | Results Johnson & Johnson investigational co-antibody therapy JNJ-4804 shows potential to raise the bar for clinical efficacy in treating refractory inflammatory bowel disease jnj.com ↗
In both studies at Week 48, JNJ-4804 showed meaningful improvements across multiple clinical and endoscopic measures for a subpopulation of patients who are considered highly refractory and have had inadequate response to two or more systemic therapy classes. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-05-05 | Janssen Research & Development, LLC | Johnson & Johnson investigational co-antibody therapy JNJ-4804 shows potential to raise the bar for clinical efficacy in treating refractory inflammatory bowel disease jnj.com ↗ |
| 2026-05-05 | Janssen Research & Development, LLC | Johnson & Johnson investigational co-antibody therapy JNJ-4804 shows potential to raise the bar for clinical efficacy in treating refractory inflammatory bowel disease jnj.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JNJ-78934804 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05242484 ↗ |
| Route | Subcutaneous | “JNJ-78934804 will be administered subcutaneously as per defined regimen.” NCT05242471 ↗ |